TEVA.N
Latest Trade
9.92USDChange
--(--)Today's Range
-
--52 Week Range
-
20.32As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 9.92 |
|---|---|
Open | -- |
Volume | -- |
3M AVG Volume | 447.72 |
Today's High | -- |
Today's Low | -- |
52 Week High | 20.32 |
52 Week Low | 6.07 |
Shares Out (MIL) | 1,092.09 |
Market Cap (MIL) | 10,830.33 |
Forward P/E | 4.15 |
Dividend (Yield %) | -- |
Teva, In Response To Report On Probe Of Opioid Makers, Distributors, Says Subpoena Referenced On Nov. 26 Was Previously Disclosed In Q3 Public Filings
Federal Prosecutors Launch Criminal Probe Of Opioid Makers, Distributors - WSJ
Health Canada Says Apotex, Astrazeneca Canada, Teva Canada Reported Tamoxifen Shortages In The Past Weeks
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.
Industry
Biotechnology & Drugs
Executive Leadership
Sol J. Barer
Independent Chairman of the Board
Kaare Schultz
President, Chief Executive Officer, Director
Mark Sabag
Executive Vice President - Global Human Resources
Iris Beck-Codner
Executive Vice President - Global Brand & Communications
Richard Daniell
Executive Vice President - European Commercial
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 0.62 |
Price To Book (MRQ) | 0.79 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 195.36 |
LT Debt To Equity (MRQ) | 172.66 |
Return on Investment (TTM) | -9.42 |
Return on Equity (TTM) | -7.00 |
Teva Pharmaceutical Industries on Monday signed research agreements with two leading Israeli academic institutes, a move to boost its early-stage drug development with a focus on cancer treatments.
Teva Pharmaceutical Industries Ltd <TEVA.TA> on Thursday expressed confidence in its ability to continue paying down its huge debt burden even if it is forced to pay billions of dollars to settle thousands of U.S. opioid lawsuits.
Israel-based Teva Pharmaceutical Industries reported a larger-than-expected drop in third-quarter profit on Thursday and slightly raised its full year outlook.
Teva Pharmaceutical Industries Ltd's proposed $23 billion drug giveaway to settle thousands of U.S. opioid lawsuits will likely cost the company a fraction of that figure due to how it has valued those medicines, according to a Reuters review of pricing data and industry...
Teva Pharmaceutical Industries Ltd's proposed $23 billion (£17.85 billion) drug giveaway to settle thousands of U.S. opioid lawsuits will likely cost the company a fraction of that figure due to how it has valued those medicines, according to a Reuters review of pricing...
Talks to reach a settlement of thousands of lawsuits stemming from the U.S. opioid addiction crisis could resume as soon as Tuesday, an attorney for local governments said on Monday.
Talks to reach a settlement of thousands of lawsuits stemming from the U.S. opioid addiction crisis could resume as soon as Tuesday, an attorney for local governments said on Monday.
Talks to reach a settlement of thousands of lawsuits stemming from the U.S. opioid addiction crisis could resume as soon as Tuesday, an attorney for local governments said on Monday.
Drug maker Teva Pharmaceutical Industries Inc <TEVA.TA> and the three biggest U.S. drug distributors reached a settlement on Monday to avoid a trial over their role in the opioid addiction crisis, a source said on Monday.
Drug maker Teva Pharmaceutical Industries Inc <TEVA.TA> and the three biggest U.S. drug distributors reached a settlement on Monday to avoid a trial over their role in the opioid addiction crisis, a source said on Monday.
McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp and Teva Pharmaceutical Industries reached a settlement with two Ohio counties related to the opioid crisis, the Wall Street Journal reported on Monday, citing sources.
Teva Pharmaceutical's UK unit has recalled some batches of heartburn medicine Ranitidine, Britain's medicines watchdog said on Thursday, making it the latest drugmaker to pull the product.
Teva Pharmaceuticals is in talks to contribute over $15 billion worth of drugs as part of a settlement to resolve lawsuits alleging it helped fuel the U.S. opioid crisis, a source familiar with the matter told Reuters on Wednesday.
Teva Pharmaceutical Industries Ltd on Tuesday made its generic version of Mylan's EpiPen for young children available in most retail pharmacies at $300 for a 2-pack.
Teva Pharmaceutical Industries Ltd said on Tuesday its generic version of Mylan's EpiPen for young children will be available in most retail pharmacies at a price of $300 for a 2-pack.
The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.
The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.
Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter profit on Wednesday and said its chief financial officer was leaving the company.
Israel-based Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter profit on Wednesday and reaffirmed its full year outlook.
An Oklahoma judge on Monday approved a revised $85 million settlement with Teva Pharmaceutical Industries Ltd resolving claims by the state's attorney general that the drugmaker helped fuel the U.S. opioid epidemic.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.